Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COG133
- Development stage
- Preclinical
- Lead developer
- Cognosci
- Modality
- Peptides
- Administration
- Intraperitoneal, Intraluminal, Intravenous, Intratracheal
01
Overview
COG133 is a synthetic, small peptide (approximately 10-17 amino acids) derived from the receptor-binding domain of apolipoprotein E (apoE). Developed by Cognosci Inc., it is designed to mimic the anti-inflammatory and neuroprotective properties of the full-length apoE protein. COG133 specifically targets the NMDA receptor to mitigate excitotoxicity and has demonstrated efficacy in animal models of Multiple Sclerosis (EAE), where it reduces relapse rates, total disability, and spinal cord demyelination. It is currently in preclinical development for both relapsing-remitting and progressive forms of Multiple Sclerosis.
- Other names
- apoE-mimetic peptideCognosci apoE peptide
02
Targets
CHRNA7 (α7 nicotinic receptor)LDLR (Low-density lipoprotein receptor)LRP1 (Prolow-density lipoprotein receptor-related protein 1)NMDAR (Glutamate receptor ionotropic, NMDA)TAFI (Carboxypeptidase B2)APOE (Apolipoprotein E)
Beyond the preview
Go deeper on COG133.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COG133.